Competitive ELISA for N-terminal pro-brain natriuretic peptide (NT-proBNP) determination in human plasma
| Autor: | Fernando Albericio, M.-Pilar Marco, Gerardo A. Acosta, Gloria Colom, Miriam Royo, J.-Pablo Salvador |
|---|---|
| Přispěvatelé: | Ministerio de Economía y Competitividad (España), Salvador, Juan Pablo, Marco, María Pilar, Salvador, Juan Pablo [0000-0002-3608-0634], Marco, María Pilar [0000-0002-2237-7197] |
| Rok vydání: | 2020 |
| Předmět: |
medicine.drug_class
Heterologous BNPs Enzyme-Linked Immunosorbent Assay Peptide 030204 cardiovascular system & hematology Pharmacology Biochemistry Analytical Chemistry 03 medical and health sciences 0302 clinical medicine Natriuretic Peptide Brain Electrochemistry Natriuretic peptide Humans Environmental Chemistry Medicine Spectroscopy Heart Failure chemistry.chemical_classification business.industry Cardiovascular disease CVD medicine.disease Peptide Fragments Brain natriuretic peptides chemistry Human plasma 030220 oncology & carcinogenesis Heart failure Biomarker (medicine) business Hapten Biomarkers N-terminal pro-Brain Natriuretic Peptide |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| ISSN: | 1364-5528 0003-2654 |
| Popis: | Brain natriuretic peptides (BNPs) are well established cardiovascular disease (CVD) biomarkers, which are released from the heart after ventricular wall stress. Particularly, the N-terminal proBNP (NT-proBNP) is a 76 aa long peptide which has been recognized as indicator for the diagnosis of heart failure (HF) and is being used in routine tests in emergency rooms, when levels are above 0.4 ng mL-1. Here we report a new competitive ELISA for NT-proBNP which is able to detect this biomarker directly in undiluted human plasma samples. The ELISA has been the result of a rational design of an immunizing peptide hapten and the investigation of different immunochemical conditions, including heterologous competitors and distinct physico-chemical conditions. The ELISA developed is able to detect NT-proBNP with a LOD of 0.40±0.15 ng mL-1 in human plasma samples and to quantify this biomarker in the range comprised between 0.97±0.38 and 23.10±9.46 ng mL-1 with a good accuracy. The ELISA can measure simultaneously many samples in 1:30 h and it has been found robust and reproducible and being a great promise for their use on the diagnosis of the heart failure. This work has been funded by CAJAL4EU project (ICT-Joint Undertaking Action ENIAC-120215; MICINN FCCI-PLE2009-0168 and MICINN EUI-ENIAC-2011-4331). The Nb4D group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (expedient: 2017 SGR 1441). CIBER-BBN is an initiative funded by the Spanish National Plan for Scientific and Technical Research and Innovation 2013-2016, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions are financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. The ICTS “NANOBIOSIS”, and particularly the Custom Antibody Service (CAbS, IQAC-CSIC, CIBER-BBN), is acknowledged for the assistance and support related to the immunoreagents used in this work. The MS4N group thanks Spanish Ministerio de Economía, Industria y Competitividad SAF2014-60138-R), CIBER-BBN (CB06-01-0074), Generalitat de Catalunya (2017SGR1439). This work was partially performed at the facilities of NANBIOSIS (Units 2 and 3). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|